Vincent Jullien

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5253856/publications.pdf

Version: 2024-02-01

623734 580821 26 783 14 25 citations g-index h-index papers 26 26 26 1325 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Facilitation of Drug Evaluation in Children byÂPopulation Methods and Modellingâ€. Clinical Pharmacokinetics, 2008, 47, 231-243.	3.5	170
2	Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, <i>Candida</i> Colonization, and Multiple Organ Failure. JAMA - Journal of the American Medical Association, 2016, 316, 1555.	7.4	152
3	Antifungal drugs during pregnancy: an updated review. Journal of Antimicrobial Chemotherapy, 2015, 70, 14-22.	3.0	103
4	Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation. Journal of Antimicrobial Chemotherapy, 2017, 72, 181-189.	3.0	46
5	An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1046, 26-33.	2.3	32
6	Isavuconazole Diffusion in Infected Human Brain. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	24
7	Reassessment of stiripentol pharmacokinetics in healthy adult volunteers. Epilepsy Research, 2014, 108, 909-916.	1.6	23
8	Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. British Journal of Clinical Pharmacology, 2017, 83, 2695-2708.	2.4	19
9	Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy. Clinical Pharmacokinetics, 2018, 57, 739-748.	3.5	19
10	Posaconazole Tablets in Real-Life Lung Transplantation: Impact on Exposure, Drug-Drug Interactions, and Drug Management in Lung Transplant Patients, Including Those with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	18
11	Low Central Nervous System Posaconazole Concentrations during Cerebral Phaeohyphomycosis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	18
12	EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial. Trials, 2013, 14, 399.	1.6	17
13	Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies. Statistical Methods in Medical Research, 2018, 27, 1860-1877.	1.5	17
14	Suboptimal Ciprofloxacin Dosing as a Potential Cause of DecreasedPseudomonas aeruginosaSusceptibility in Children with Cystic Fibrosis. Pharmacotherapy, 2010, 30, 1252-1258.	2.6	16
15	Levetiracetam optimal dose-finding as first-line treatment for neonatal seizures occurring in the context of hypoxic-ischaemic encephalopathy (LEVNEONAT-1): study protocol of a phase II trial. BMJ Open, 2019, 9, e022739.	1.9	15
16	Pharmacokinetics of Clobazam and N-Desmethylclobazam in Children with Dravet Syndrome Receiving Concomitant Stiripentol and Valproic Acid. Clinical Pharmacokinetics, 2015, 54, 527-536.	3.5	14
17	Failure of voriconazole therapy due to acquired azole resistance in Aspergillus fumigatus in a kidney transplant recipient with chronic necrotizing aspergillosis. American Journal of Transplantation, 2018, 18, 2352-2355.	4.7	14
18	Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions. Clinical Pharmacokinetics, 2021, 60, 409-445.	3.5	12

#	Article	IF	CITATIONS
19	Determination of the R (â^') and S (+)-enantiomers of vigabatrin in human plasma by ultra-high-performance liquid chromatography and tandem mass-spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1070, 31-36.	2.3	10
20	A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy. European Journal of Clinical Pharmacology, 2018, 74, 793-803.	1.9	10
21	ls It Time for Systematic Voriconazole Pharmacogenomic Investigation for Central Nervous System Aspergillosis?. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	8
22	Proposition of a Minimal Effective Dose of Vigabatrin for the Treatment of Infantile Spasms Using Pediatric and Adult Pharmacokinetic Data. Journal of Clinical Pharmacology, 2019, 59, 177-188.	2.0	8
23	Acute reversible pancreatitis induced by posaconazole. Journal of Antimicrobial Chemotherapy, 2017, 72, 628-630.	3.0	6
24	Pharmacokinetic evaluation of vigabatrin dose for the treatment of refractory focal seizures in children using adult and pediatric data. Epilepsy Research, 2019, 150, 38-45.	1.6	6
25	In Vivo Efficacy of Voriconazole in a Galleria mellonella Model of Invasive Infection Due to Azole-Susceptible or Resistant Aspergillus fumigatus Isolates. Journal of Fungi (Basel, Switzerland), 2021, 7, 1012.	3.5	6
26	Unintentional artenimol/piperaquine overdose in two children occurring without evidence of subsequent cardiotoxicity. International Journal of Antimicrobial Agents, 2021, 57, 106347.	2.5	0